Clinical Trial

Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Treatment with olutasidenib for isocitrate dehydrogenase 1 (IDH1) mutant acute myeloid leukemia (AML) after completion of traditional intensive induction/consolidation is likely to be safe, tolerable, and may provide clinical benefit in terms of maintenance of remission and perhaps improvement in survival.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-15; most recent amendment 2026-02-03.
Status change: Not Yet Recruiting → Recruiting 2026-02-03
Trial Details
NCT Number NCT07130695
Lead Sponsor Virginia Commonwealth University
Collaborators: Rigel Pharmaceuticals
Conditions Acute Myeloid Leukemia
Enrollment 15 participants
Start Date 2026-02-02
Primary Completion 2028-10-31 (estimated)
Study Completion 2030-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-06